Reducing Lung Cancer-Related Anxiety (RELAX)

(RELAX Trial)

Recruiting in Palo Alto (17 mi)

+10 other locations

Overseen by Glenn Lesser, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Wake Forest University Health Sciences

No Placebo Group

Trial Summary

What is the purpose of this trial?

The purpose of this research study is to compare the effects of music and different levels of device-guided breathing on anxiety and shortness of breath in lung cancer survivors.

Research Team

Suzanne C Danhauer, PhD

Principal Investigator

Wake Forest University Health Sciences

Glenn Lesser, MD

Principal Investigator

Wake Forest University Health Sciences

Eligibility Criteria

Inclusion Criteria

Past History of any lung cancer

For Stage I-III disease, patients should be 2-24 months post-completion of surgery, radiation therapy and/or chemotherapy with no further planned treatment during the 12-week study and no evidence of disease.

For Stage IV disease, patients may be receiving no treatment or may be receiving maintenance treatment with a target agent, chemotherapy, or immunotherapy provided the most recent imaging does not demonstrate progressive disease.

Treatment Details

Interventions

• Device guided breathing high dose (Behavioural Intervention)
• Device guided breathing low dose (Behavioural Intervention)
• Usual Breathing Control Group (Behavioural Intervention)

Participant Groups

Group I: Group B Experimental Treatment 1 Intervention

Group B - Device guided breathing high dose

Group II: Group A Experimental Treatment 1 Intervention

Group A - Device Guided Breathing Low Dose

Group III: Group C Placebo Group 1 Intervention

Group C - Usual Breathing Control Group

Who Is Running the Clinical Trial?

Wake Forest University Health Sciences

Lead Sponsor

Trials

1,432

Recruited

2,506,000+

Dr. L. Ebony Boulware

Wake Forest University Health Sciences

Chief Medical Officer since 2022

MD from Duke University School of Medicine, MPH from Johns Hopkins Bloomberg School of Public Health

Dr. Julie Ann Freischlag

Wake Forest University Health Sciences

Chief Executive Officer since 2020

BS from University of Illinois, MD from Rush University

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

Dr. Douglas R. Lowy

National Cancer Institute (NCI)

Chief Executive Officer since 2023

MD from New York University School of Medicine

Dr. Monica Bertagnolli

National Cancer Institute (NCI)

Chief Medical Officer since 2022

MD from Harvard Medical School